Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

5-year TVF and MACCE in patients with deferred of revascularization after FFR: Is FFR enough?

Fractional flow reserve (FFR) has been shown effective and safe by different studies, yet not at 5 years. 

Eventos cardiovasculares a 5 años luego de postergar la revascularización guiada por FFR, ¿Debemos guiarnos sólo por el valor obtenido con esta técnica? 

The aim of this multicenter registry was to assess the impact of thrombotic risk (as per CREDO-Kyoto score) as a predictor of cardiovascular events at 5 years in patients with deferred revascularization after FFR measurement. 

The score used in this study was only validated for the Japanese population; it includes variables such as chronic kidney failure, atrial fibrillation, peripheral vascular disease, anemia, age >75, cardiac failure and diabetes. 

Cardiovascular events related to the treated vessel were considered target vessel failure (TVF), and defined as a composite of cardiovascular death, target vessel MI, and clinically driven TVF, while patient related events were considered MACCE (including total death, cerebrovascular events, AMI and revascularization). 

Read also: ACC 2022 | SPYRAL HTN-ON: Is It Time to Start Using Renal Denervation?

They looked at 1263 patients, mean age 70, mostly hypertensive and dyslipidemic. The most frequent clinical presentation was stable angina, and the anterior descending was the most treated vessel. 

At 5 years, patients at high risk, according to this score, showed greater MACE rate, at the expense of all cause death. In addition, this group of patients presented a higher rate of TVF. Patients with positive FFR had a higher incidence of TVF at the expense of clinical guided revascularization at 5 years. 

There were no differences in MACCE between FFR positive and negative patients at 5 years.

Read also: ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions.

Patients at high risk of thrombosis and negative FFR presented the highest rate of TVF and MACCE. 

Conclusion

Among CAD patients with deferred revascularization after FFR, thrombotic risk and FFR value were associated to MACCE and TVF at 5 years. Patients with high thrombosis risk presented the highest risk, even with negative FFR. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez
Member of the Editorial Board in SOLACI.org .

Original Title: Thrombotic Risk and Cardiovascular Events in Patients With Revascularization Deferral After Fractional Flow Reserve Assessment.

Reference: Yasutsugu Shiono, MD, PHD et al J Am Coll Cardiol Intv 2022;15:427–439.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...